Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Stock Short Interest Report for October

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the target of a significant drop in short interest in October. As of October 30th, there was short interest totaling 2,140 shares, a drop of 88.8% from the October 15th total of 19,178 shares. Based on an average daily volume of 241,294 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s stock are sold short.

Wall Street Analyst Weigh In

DSNKY has been the topic of a number of analyst reports. Jefferies Financial Group cut Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Zacks Research downgraded Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Daiichi Sankyo has a consensus rating of “Reduce”.

Daiichi Sankyo Stock Up 2.2%

Shares of OTCMKTS DSNKY traded up $0.38 during midday trading on Thursday, hitting $17.89. The stock had a trading volume of 9,694 shares, compared to its average volume of 308,422. The business’s 50 day moving average is $17.79 and its 200-day moving average is $17.56. Daiichi Sankyo has a 52 week low of $14.98 and a 52 week high of $24.77. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29. The company has a market cap of $33.32 billion, a P/E ratio of 18.25, a PEG ratio of 2.02 and a beta of -0.10.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings results on Friday, October 30th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.08. Daiichi Sankyo had a net margin of 12.13% and a return on equity of 16.31%. The company had revenue of $3.77 billion during the quarter, compared to the consensus estimate of $3.58 billion. As a group, analysts predict that Daiichi Sankyo will post 0.87 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions. Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib).